Biotechnology Analysts Kluska and Miller, along with President & CEO Niklason and CFO Sander, discuss potential Phase 2/3 (V005) trial data for HAV in vascular trauma, which is guided to report top-line data by the end of 3Q23, on a conference call to be held on August 23 at 1 pm hosted by Cantor Fitzgerald. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HUMA:
- Humacyte participates in a conference call with Cantor Fitzgerald
- Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program
- Humacyte presents clinical performance of HAV from Ukranian Humanitarian Program
- Humacyte (NASDAQ:HUMA) Surges With New Analyst Upgrade
- Cantor a buyer of Humacyte into Q3 V005 data
